Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00136084 · ClinicalTrials.gov registry record · Phase 3

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

A Phase 3 study, sponsored by St. Jude Children's Research Hospital.

Completed
Registry status
Phase 3
Development phase
238
Enrollment target

NCT00136084 is a Phase 3 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 238 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00136084, a Phase 3 study, has completed, sponsored by St. Jude Children's Research Hospital.

COMPLETED
Registry status
Phase 3
Development phase
238 participants
Enrollment target

Study Summary

The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.

Interventions

  • DRUG Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
  • DRUG Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine

Trial Details

FieldValue
Enrollment Target 238 participants
Start Date 2002-08
Est. Completion 2012-06
Phase Phase 3

What the Registry Record Tells You About NCT00136084

The ClinicalTrials.gov registry entry for NCT00136084 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone is the first listed.

NCT00136084 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00136084 about?

NCT00136084 is a clinical study titled "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia". The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.

What is the current status of trial NCT00136084?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2002-08. Estimated completion is 2012-06.

What interventions are being tested in trial NCT00136084?

The interventions under investigation include: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone (DRUG), Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine (DRUG).

Who is sponsoring clinical trial NCT00136084?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.